BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 12270727)

  • 1. Induction of B- and T-cell responses to cruzipain in the murine model of Trypanosoma cruzi infection.
    Schnapp AR; Eickhoff CS; Scharfstein J; Hoft DF
    Microbes Infect; 2002 Jul; 4(8):805-13. PubMed ID: 12270727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cruzipain induces both mucosal and systemic protection against Trypanosoma cruzi in mice.
    Schnapp AR; Eickhoff CS; Sizemore D; Curtiss R; Hoft DF
    Infect Immun; 2002 Sep; 70(9):5065-74. PubMed ID: 12183554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cruzipain and Its Physiological Inhibitor, Chagasin, as a DNA-Based Therapeutic Vaccine Against
    Cerny N; Bivona AE; Sanchez Alberti A; Trinitario SN; Morales C; Cardoso Landaburu A; Cazorla SI; Malchiodi EL
    Front Immunol; 2020; 11():565142. PubMed ID: 33162979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heterologous Chimeric Construct Comprising a Modified Bacterial Superantigen and a Cruzipain Domain Confers Protection Against
    Antonoglou MB; Sánchez Alberti A; Redolfi DM; Bivona AE; Fernández Lynch MJ; Noli Truant S; Sarratea MB; Iannantuono López LV; Malchiodi EL; Fernández MM
    Front Immunol; 2020; 11():1279. PubMed ID: 32695105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis and partial epitope mapping of human T cell responses to Trypanosoma cruzi cysteinyl proteinase.
    Arnholdt AC; Piuvezam MR; Russo DM; Lima AP; Pedrosa RC; Reed SG; Scharfstein J
    J Immunol; 1993 Sep; 151(6):3171-9. PubMed ID: 7690795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral vaccination with Salmonella enterica as a cruzipain-DNA delivery system confers protective immunity against Trypanosoma cruzi.
    Cazorla SI; Becker PD; Frank FM; Ebensen T; Sartori MJ; Corral RS; Malchiodi EL; Guzmán CA
    Infect Immun; 2008 Jan; 76(1):324-33. PubMed ID: 17967857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prime-boost immunization with cruzipain co-administered with MALP-2 triggers a protective immune response able to decrease parasite burden and tissue injury in an experimental Trypanosoma cruzi infection model.
    Cazorla SI; Frank FM; Becker PD; Corral RS; Guzmán CA; Malchiodi EL
    Vaccine; 2008 Apr; 26(16):1999-2009. PubMed ID: 18342408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic immunization elicits antigen-specific protective immune responses and decreases disease severity in Trypanosoma cruzi infection.
    Garg N; Tarleton RL
    Infect Immun; 2002 Oct; 70(10):5547-55. PubMed ID: 12228281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trans-sialidase recombinant protein mixed with CpG motif-containing oligodeoxynucleotide induces protective mucosal and systemic trypanosoma cruzi immunity involving CD8+ CTL and B cell-mediated cross-priming.
    Hoft DF; Eickhoff CS; Giddings OK; Vasconcelos JR; Rodrigues MM
    J Immunol; 2007 Nov; 179(10):6889-900. PubMed ID: 17982080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trypanosoma cruzi: the major cysteinyl proteinase (cruzipain) is a relevant immunogen of parasite acidic antigens (FIII).
    Laderach D; Cerban F; Motran C; Vottero de Cima E; Gea S
    Int J Parasitol; 1996 Nov; 26(11):1249-54. PubMed ID: 9024869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Redirection of the immune response to the functional catalytic domain of the cystein proteinase cruzipain improves protective immunity against Trypanosoma cruzi infection.
    Cazorla SI; Frank FM; Becker PD; Arnaiz M; Mirkin GA; Corral RS; Guzmán CA; Malchiodi EL
    J Infect Dis; 2010 Jul; 202(1):136-44. PubMed ID: 20497050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Type 1 immunity provides optimal protection against both mucosal and systemic Trypanosoma cruzi challenges.
    Hoft DF; Eickhoff CS
    Infect Immun; 2002 Dec; 70(12):6715-25. PubMed ID: 12438346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cruzipain, a major Trypanosoma cruzi antigen, conditions the host immune response in favor of parasite.
    Giordanengo L; Guiñazú N; Stempin C; Fretes R; Cerbán F; Gea S
    Eur J Immunol; 2002 Apr; 32(4):1003-11. PubMed ID: 11920566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trypanosoma cruzi 80 kDa prolyl oligopeptidase (Tc80) as a novel immunogen for Chagas disease vaccine.
    Bivona AE; Sánchez Alberti A; Matos MN; Cerny N; Cardoso AC; Morales C; González G; Cazorla SI; Malchiodi EL
    PLoS Negl Trop Dis; 2018 Mar; 12(3):e0006384. PubMed ID: 29601585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Previously unrecognized vaccine candidates control Trypanosoma cruzi infection and immunopathology in mice.
    Bhatia V; Garg NJ
    Clin Vaccine Immunol; 2008 Aug; 15(8):1158-64. PubMed ID: 18550728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human T cell responses against the major cysteine proteinase (cruzipain) of Trypanosoma cruzi: role of the multifunctional alpha 2-macroglobulin receptor in antigen presentation by monocytes.
    Morrot A; Strickland DK; Higuchi Mde L; Reis M; Pedrosa R; Scharfstein J
    Int Immunol; 1997 Jun; 9(6):825-34. PubMed ID: 9199965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prophylactic efficacy of TcVac2 against Trypanosoma cruzi in mice.
    Gupta S; Garg NJ
    PLoS Negl Trop Dis; 2010 Aug; 4(8):e797. PubMed ID: 20706586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trypanosoma cruzi antigen immunization induces a higher B cell survival in BALB/c mice, a susceptible strain, compared to C57BL/6 B lymphocytes, a resistant strain to cardiac autoimmunity.
    Pellegrini A; Carrera-Silva EA; Arocena A; Cano RC; Aoki MP; Gea S
    Med Microbiol Immunol; 2011 Nov; 200(4):209-18. PubMed ID: 21431877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccination with trypomastigote surface antigen 1-encoding plasmid DNA confers protection against lethal Trypanosoma cruzi infection.
    Wizel B; Garg N; Tarleton RL
    Infect Immun; 1998 Nov; 66(11):5073-81. PubMed ID: 9784506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression, purification, immunogenicity, and protective efficacy of a recombinant Tc24 antigen as a vaccine against Trypanosoma cruzi infection in mice.
    Martinez-Campos V; Martinez-Vega P; Ramirez-Sierra MJ; Rosado-Vallado M; Seid CA; Hudspeth EM; Wei J; Liu Z; Kwityn C; Hammond M; Ortega-López J; Zhan B; Hotez PJ; Bottazzi ME; Dumonteil E
    Vaccine; 2015 Aug; 33(36):4505-12. PubMed ID: 26192358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.